|
| Press Releases |
|
 |
|
| Monday, November 17, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. more info >> |
|
| Thursday, October 30, 2025 |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| more info >> |
|
| Tuesday, October 28, 2025 |
|
|
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma |
| more info >> |
|
| Monday, October 27, 2025 |
|
|
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease |
| more info >> |
|
| Tuesday, October 14, 2025 |
|
|
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI(R) IQLIK(TM), a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions of 2025" in the Medical and Healthcare category. more info >> |
|
| Wednesday, October 8, 2025 |
|
|
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIK(TM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Friday, October 3, 2025 |
|
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2025, which is taking place in Berlin, Germany from October 17 to 21. more info >> |
|
| Monday, September 29, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Wednesday, September 24, 2025 |
|
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers. more info >> |
|
| Wednesday, September 17, 2025 |
|
|
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
TransNusa Expands Regional Network With Launch of Jakarta-Penang Route
Nov 24, 2025 12:30 HKT/SGT
|
|
|
PLN Strengthens Its Pathway to the Global Carbon Market Through Energy Transition Investments 
Nov 24, 2025 12:00 HKT/SGT
|
|
|
IMPC Commits Rp250 billion (USD 15 million) to Build ASEAN's Leading Polymer Training Center, Partnering with SKZ-German Plastics Center
Nov 24, 2025 10:00 HKT/SGT
|
|
|
Global Blockchain Show 2025 to Spotlight Web3 Innovation in Abu Dhabi
Nov 24, 2025 06:24 HKT/SGT
|
|
|
playX Receives the 'Enterprise Award' at the Asia Golden Star Awards in Tokyo
Nov 22, 2025 14:00 HKT/SGT
|
|
|
DOCOMO Wins Gold Medal in Kaggle, the World's Largest AI Data Science Competition
Nov 21, 2025 0:39 JST
|
|
|
Fujitsu launches integrated package of core system support services for food distribution industry
Nov 21, 2025 0:04 JST
|
|
|
PLN Reaffirms Commitment to Advancing a Just Energy Transition at COP30
Nov 21, 2025 16:00 HKT/SGT
|
|
|
Kyrgyz Republic Launches First Issuance of Gold-Backed Stablecoin USDKG
Nov 21, 2025 13:00 HKT/SGT
|
|
|
OMP Miami Conference 2025: Transforming Supply Chain Vision into REAL Impact with Human-AI Synergy
Nov 20, 2025 23:00 HKT/SGT
|
|
|
Doubleview Gold Corp. Highlights Scandium Potential at Hat Project, a Key Enabler for the Electrification Economy
Nov 20, 2025 22:09 HKT/SGT
|
|
|
U.S. Polo Assn. Receives Multiple Global Honors Recognizing Excellence in Brand, Content, and Digital Growth
Nov 20, 2025 20:00 HKT/SGT
|
|
|
BIP Asia Forum and Entrepreneur Day set for December
Nov 20, 2025 18:29 HKT/SGT
|
|
|
WASH debuts on MAI, targeting 160 new branches for 2026-2027
Nov 20, 2025 17:00 HKT/SGT
|
|
|
Shoucheng Holdings Launches 'Robot Tech Experience Store' Naming Vote
Nov 20, 2025 16:10 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
